Treatment of Follicular Non-Hodgkin's Lymphoma: The Old and the New

Seminars in Hematology

Volumn 45, Issue SUPPL.2, 2008, Pages S2-

  Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 263; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; IBRITUMOMAB Y 90; LENALIDOMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISOLONE; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; FOLLICULAR LYMPHOMA; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY;

EID: 50049092599     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.07.003     Document Type: Article

References (39)

1. Fisher R.I., Kaminski M.S., Wahl R.L., Knox S.J., Zelenetz A.D., Vose J.M., et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 23 (2005) 7565-7573
2. Halaas J.L., Teruya-Feldstein J., Filippa D.A., Chaya M., Naresh K.N., and Zelenetz A.D. The Follicular Lymphoma International Prognostic Index (FLIPI) Is superior to WHO/REAL histological grade for identifying high-risk patients: A retrospective review of the MSKCC experience in 260 patients with follicular lymphoma. Blood 104 (2004) 892a (abstr 3268)
3. Solal-Celigny P., Roy P., Colombat P., White J., Armitage J.O., Arranz-Saez R., et al. Follicular lymphoma international prognostic index. Blood 104 (2004) 1258-1265
4. Buske C., Hoster E., Dreyling M., Hasford J., Unterhalt M., and Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108 (2006) 1504-1508
5. An observational study of treatment, outcomes, and prognosis in patients with follicular non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00097565 Accessed January 22, 2008
6. Link B.K., Cerhan J.R., Dillon H., Farber C.M., Feliciano S., Friedberg J.W., et al. Prospective validation of the FLIPI: Baseline distribution and correlates in newly diagnosed follicular lymphoma (FL) patients from the US: First report of the National Lympho-Care Study. Blood 106 (2005) 293a (abstr 1000)
7. Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (2005) 3725-3732
8. Hiddemann W., Forstpointner R., Kneba M., Schmitz N., Schmits R., Metner B., et al. The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: Results of two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG). Blood 104 (2004) 50a (abstr)
9. Foussard C., Mounier N., Van Hoof A., Delwail V., Casasnovas O., Deconinck E., et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol 24 (2006) 7508 (abstr)
10. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
11. Marcus R.E., Solal-Celigny P., Imrie K., Cunningham D., Flores E., Catalano J., et al. MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkins lymphoma (NHL). Blood 108 (2006) 146a (abstr 481)
12. Herold M., Haas A., Srock S., Neser S., Al Ali K., Neubauer A., et al. Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma-4 year follow-up results of a phase III trial of East German Study Group Hematology and Oncology (OSHO#39). Blood 108 (2006) 147a (abstr 484)
13. Friedberg J.W., Huang J., Dillon H., Farber C., Feliciano S., Hainsworth J., et al. Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). Proc Am Soc Clin Oncol 24 (2006) 428s (abstr 7527)
14. Rituximab in treating patients with low tumor burden indolent non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00075946 Accessed January 22, 2008
15. Primary rituximab and maintenance. http://clinicaltrials.gov/ct2/show/NCT00140582 Accessed January 22, 2008
16. Combination chemotherapy with monoclonal antibody therapy in treating patients with newly diagnosed non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00006721 Accessed January 22, 2008
17. Hainsworth J.D., Litchy S., Shaffer D.W., Lackey V.L., Grimaldi M., and Greco F.A. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23 (2005) 1088-1095
18. Rohatiner A.Z., Nadler L., Davies A.J., Apostolidis J., Neuberg D., Matthews J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 25 (2007) 2554-2559
19. Horning S.J., Younes A., Jain V., Kroll S., Lucas J., Podoloff D., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23 (2005) 712-719
20. Witzig T.E., Flinn I.W., Gordon L.I., Emmanouilides C., Czuczman M.S., Saleh M.N., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3262-3269
21. Friedberg J.W., Cohen P., Chen L., Robinson K.S., Forero-Torres A., La Casce A.S., et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 26 (2008) 204-210
22. Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N., et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67 (2007) 6383-6391
23. Ahn K.S., Sethi G., Chao T.H., Neuteboom S.T., Chaturvedi M.M., Palladino M.A., et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood 110 (2007) 2286-2295
24. Chauhan D., Velankar M., Brahmandam M., Hideshima T., Podar K., Richardson P., et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26 (2007) 2374-2380
25. O'Connor O.A., Wright J., Moskowitz C., Muzzy J., MacGregor-Cortelli B., Stubblefield M., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 (2005) 676-684
26. O'Connor O.A. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 6 (2005) 191-199
27. Leonard J.P., Furman R.R., and Coleman M. Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer 119 (2006) 971-979
28. Stewart K.A. Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol 25 (2007) 441s (abstr 8003)
29. De Vos S., Dakhil S.R., McLaughlin P., Saleh M.N., Belt R., Flowers C., et al. Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results. Blood 108 (2006) 208a (abstr 694)
30. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4 (2004) 314-322
31. Witzig T.E., Vose J., Pietronigro D., Takeshita K., Ervin-Haynes A., Zeldis J., et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin. J Clin Oncol 25 (2007) 457s (abstr 8066)
32. Ghobrial I.M., Witzig T.E., and Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55 (2005) 178-194
33. Goy A. New directions in the treatment of mantle cell lymphoma: An overview. Clin Lymphoma Myeloma 7 Suppl 1 (2006) S24-S32
34. Ramanarayanan J., Hernandez-Ilizaliturri F.J., Chanan-Khan A., and Czuczman M.S. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol 127 (2004) 519-530
35. Chanan-Khan A. Bcl-2 antisense therapy in hematologic malignancies. Curr Opin Oncol 16 (2004) 581-585
36. Chanan-Khan A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev 19 (2005) 213-221
37. Goy A., Ford P., Feldman T., Pecora A., Goldberg S., Donato M., et al. A phase 1 trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma. Blood 110 (2007) 757a (abstr 2569)
38. Wilson W.H., Tulpule A., Levine A.M., Dunleavy K., Krivoshik A.P., Hagey A., et al. A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood 110 (2007) 412a (abstr 1371)
39. Blagosklonny M.V. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther 4 (2005) 1307-1310